2023
Anti-Müllerian Hormone Level Decline in Patients Undergoing Hysterectomy With and Without Oophorectomy Compared With Natural Menopause
Santoro N, Flyckt R, Davis A, Finkelstein J, Crawford S, Sun F, Derby C, Morrison A, Sluss P, Zhang H. Anti-Müllerian Hormone Level Decline in Patients Undergoing Hysterectomy With and Without Oophorectomy Compared With Natural Menopause. Obstetrics And Gynecology 2023, 141: 331-340. PMID: 36649324, PMCID: PMC9858351, DOI: 10.1097/aog.0000000000005049.Peer-Reviewed Original ResearchConceptsFinal menstrual periodAnti-Müllerian hormone levelsAMH levelsNatural menopauseHormone levelsUndetectable AMH levelsCommunity-based studyOvarian conservationOvarian reserveAMH measurementOvarian failureMenstrual periodSurgery dateHysterectomyLinear mixed modelingMenopauseSurvival analysisPatientsImmediate reductionMixed modelingWomenOvariesSimilar patternRapid declineBSO
2022
Biomarkers of Stress and Male Fertility
Spitzer TL, Trussell JC, Coward RM, Hansen KR, Barnhart KT, Cedars MI, Diamond MP, Krawetz SA, Sun F, Zhang H, Santoro N, Steiner AZ. Biomarkers of Stress and Male Fertility. Reproductive Sciences 2022, 29: 1262-1270. PMID: 35106743, PMCID: PMC9078052, DOI: 10.1007/s43032-022-00853-x.Peer-Reviewed Original ResearchConceptsLive birth rateSemen parametersSalivary levelsSperm countPregnancy/live birth rateBirth rateTotal motile sperm countMale factor infertilityMotile sperm countDNA fragmentationTotal sperm countSalivary cortisol levelsMale fertilityStress-related biomarkersChi-square testingSalivary alpha-amylaseInfertility trialsCohort studyHighest quintileIntrauterine inseminationPregnancy rateUpper quintileInfertile menPhysiologic measuresBiomarkers of stressA personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence
Souter I, Sun F, Zhang H, Diamond MP, Legro RS, Wild RA, Hansen KR, Santoro N, Network F. A personalized medicine approach to ovulation induction/ovarian stimulation: development of a predictive model and online calculator from level-I evidence. Fertility And Sterility 2022, 117: 408-418. PMID: 35125179, PMCID: PMC8985501, DOI: 10.1016/j.fertnstert.2021.10.024.Peer-Reviewed Original ResearchMeSH KeywordsAdultBody Mass IndexClinical Decision-MakingCoitusDecision Support TechniquesFemaleFertilityFertility Agents, FemaleHumansInfertility, FemaleInsemination, ArtificialMaleMaternal AgeOvulation InductionPolycystic Ovary SyndromePrecision MedicinePregnancyPregnancy RateRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTreatment OutcomeConceptsCumulative pregnancy rateAntimüllerian hormone levelsBody mass indexMultiple pregnanciesPregnancy rateClinical pregnancyOvulation inductionOvarian responseMedication doseMass indexHormone levelsLower body mass indexPregnancy rate/cyclePartner ageHigh antral follicle countLower medication doseMultiple Intrauterine GestationsMultiple pregnancy rateAntral follicle countPolycystic ovary syndromeCharacteristic curveMultivariable regression modelsPersonalized medicine approachGonadotropin useIndividualized chance
2021
The relationship of plasma antioxidant levels to semen parameters: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial
Knudtson JF, Sun F, Coward RM, Hansen KR, Barnhart KT, Smith J, Legro RS, Diamond MP, Krawetz SA, Zhang H, Usadi R, Baker VL, Santoro N, Steiner AZ. The relationship of plasma antioxidant levels to semen parameters: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Journal Of Assisted Reproduction And Genetics 2021, 38: 3005-3013. PMID: 34455507, PMCID: PMC8609082, DOI: 10.1007/s10815-021-02301-2.Peer-Reviewed Original ResearchConceptsPlasma antioxidant levelsLive birthsClinical trialsSemen parametersAntioxidant levelsVitamin ERank sum testSecondary analysisClinical outcomesNormal rangeBaseline plasma valuesVitamin E levelsWilcoxon rank sum testMale fertilityConclusionsAmong menPrimary endpointDNA fragmentationResultsAt baselineSerum levelsFertility centerE levelsMethodsThis studyMale infertilityFertility outcomesPlasma valuesMale vitamin D status and male factor infertility
Banks N, Sun F, Krawetz SA, Coward RM, Masson P, Smith JF, Trussell JC, Santoro N, Zhang H, Steiner AZ. Male vitamin D status and male factor infertility. Fertility And Sterility 2021, 116: 973-979. PMID: 34289935, PMCID: PMC8561776, DOI: 10.1016/j.fertnstert.2021.06.035.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAdultBiomarkersClomipheneDietary SupplementsDouble-Blind MethodFemaleFertilityFertility Agents, FemaleHumansInfertility, MaleInsemination, Artificial, HomologousLive BirthMalePregnancyPregnancy RateProspective StudiesRisk FactorsSemenSemen AnalysisTime FactorsTreatment OutcomeUnited StatesVitamin DVitamin D DeficiencyConceptsVitamin D deficiencyLive birth rateMale factor infertilityD deficiencyFactor infertilityD levelsSemen parametersMild male factor infertilityMale partnersVitamin D levelsVitamin D statusRate of miscarriageFemale partnersSperm concentrationBirth rateClinical pregnancyClomiphene citrateD statusDNA fragmentationCumulative pregnancySperm DNA fragmentationVitamin DFertility centerIntrauterine inseminationMonth 4
2020
Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth
Engmann L, Sun F, Legro RS, Diamond MP, Zhang H, Santoro N, Bartlebaugh C, Dodson W, Estes S, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Coutifaris C, Lecks K, Martino L, Marunich R, Snyder P, Alvero R, Comfort A, Crow M, Schlaff W, Casson P, Hohmann A, Mallette S, Christman G, Ohl D, Ringbloom M, Tang J, Bates G, Mason S, DiMaria N, Usadi R, Lucidi R, Rhea M, Baker V, Turner K, Trussell J, DelBasso D, Huang H, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Lamar C, DePaolo L, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Factors associated with study protocol adherence and bio banking participation in reproductive medicine clinical trials and their relationship to live birth. Human Reproduction 2020, 35: 2819-2831. PMID: 33190149, PMCID: PMC8453415, DOI: 10.1093/humrep/deaa232.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeClinical trial protocolMedicine clinical trialsU10 HD055942U10 HD38998Baseline characteristicsTrial protocolClinical trialsLive birthsPolycystic Ovary Syndrome IIU10 HD38992U10 HD39005U10 HD27049STUDY FUNDING/COMPETINGMultiple Intrauterine GestationsStudy protocol adherenceUS multicenter trialRegular ovulatory cyclesClinical trial findingsPolycystic ovarian morphologyPARTICIPANTS/MATERIALSROLE OF CHANCELower household incomeAfrican AmericansAspects of adherenceShort-term weight change and live birth among women with unexplained infertility and polycystic ovary syndrome undergoing ovulation induction
Vitek W, Sun F, Hoeger KM, Santoro N, Diamond MP, Zhang H, Legro RS, Network E, Coutifaris C, Christman G, Robinson R, Brzyski R, Schlaff W, Casson P, Trussell J, Eisenberg E, Lamar C, DePaolo L. Short-term weight change and live birth among women with unexplained infertility and polycystic ovary syndrome undergoing ovulation induction. Fertility And Sterility 2020, 114: 1032-1039. PMID: 33036790, PMCID: PMC7953832, DOI: 10.1016/j.fertnstert.2020.06.002.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeShort-term weight changeUnexplained infertilityLive birth rateOvulation inductionOvary syndromeWeight changeWeight gainCycles of clomipheneBody mass indexMean weight changeBirth rateRandomized trialsMass indexRegular intercourseIntrauterine inseminationTreatment allocationLive birthsMAIN OUTCOMESecondary analysisWomenWeight assessmentBirthSyndromeInfertilityAndrogenicity and fertility treatment in women with unexplained infertility
Wang ET, Diamond MP, Alvero R, Casson P, Christman GM, Coutifaris C, Hansen KR, Sun F, Legro RS, Robinson RD, Usadi RS, Pisarska MD, Santoro NF, Zhang H, Network I. Androgenicity and fertility treatment in women with unexplained infertility. Fertility And Sterility 2020, 113: 636-641. PMID: 32192596, PMCID: PMC7088440, DOI: 10.1016/j.fertnstert.2019.10.034.Peer-Reviewed Original ResearchConceptsLive birth rateBody mass indexUnexplained infertilityClinical pregnancyMass indexPregnancy lossClinical markersLive birthsAndrogenic activityFree androgen index valuesHigher body mass indexMultivariable logistic regression modelMultiple Intrauterine GestationsNormal uterine cavityHigh waist circumferenceOvarian stimulation treatmentPatent fallopian tubesBirth rateLogistic regression modelsAndrogen markersSerum TTOvarian stimulationRegular mensesInfertility populationIntrauterine gestation
2019
Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index
Rios JS, Greenwood EA, Pavone MEG, Cedars MI, Legro RS, Diamond MP, Santoro N, Sun F, Robinson RD, Christman G, Zhang H, Huddleston HG. Associations Between Anti-Mullerian Hormone and Cardiometabolic Health in Reproductive Age Women Are Explained by Body Mass Index. The Journal Of Clinical Endocrinology & Metabolism 2019, 105: dgz012. PMID: 31586179, PMCID: PMC7024739, DOI: 10.1210/clinem/dgz012.Peer-Reviewed Original ResearchConceptsHomeostasis model assessment-insulin resistancePolycystic ovary syndromeAnti-Mullerian hormoneBody mass indexC-reactive proteinUnexplained infertilityWaist circumferenceOVA groupLipoprotein cholesterolMass indexRelationship of AMHModel assessment-insulin resistanceHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolSite-adjusted modelsAssessment-insulin resistanceAntral follicle countCardio-metabolic healthReproductive-aged womenMultivariable linear regression modelsReproductive-age womenClinical populationsLow-density lipoproteinCardiometabolic agingCardiometabolic indicesLower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility
Huang H, Kuang H, Sun F, Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson PR, Christman GM, Hansen KR, Santoro N, Eisenberg E, Zhang H, Network E. Lower prevalence of non–cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility. Fertility And Sterility 2019, 111: 1011-1019.e1. PMID: 30926125, PMCID: PMC6487215, DOI: 10.1016/j.fertnstert.2019.01.020.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeUnexplained infertilityUterine fibroidsLow prevalenceOvary syndromeDifferent body mass index (BMI) groupsBody mass index groupsHigher body mass indexHigher total testosteroneNormal uterine cavityAssessment-insulin resistanceBody mass indexRandomized clinical trialsCurrent alcohol usersPrevalence of womenTotal testosteroneCurrent smokersInfertile womenLarge fibroidsMass indexInfertile patientsInsulin resistanceUterine cavityClinical trialsLower percentage
2018
Comparison of sonohysterography to hysterosalpingogram for tubal patency assessment in a multicenter fertility treatment trial among women with polycystic ovary syndrome
Christianson MS, Legro RS, Jin S, Eisenberg E, Diamond MP, Hansen KR, Vitek W, Styer AK, Casson P, Coutifaris C, Christman GM, Alvero R, Puscheck EE, Christy AY, Sun F, Zhang H, Polotsky AJ, Santoro N. Comparison of sonohysterography to hysterosalpingogram for tubal patency assessment in a multicenter fertility treatment trial among women with polycystic ovary syndrome. Journal Of Assisted Reproduction And Genetics 2018, 35: 2173-2180. PMID: 30194618, PMCID: PMC6289919, DOI: 10.1007/s10815-018-1306-2.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeSaline infusion sonohysterographyTubal patencyClinical pregnancyOvary syndromePolycystic Ovary Syndrome IITubal patency assessmentClinical pregnancy rateDuration of infertilityAcceptable imaging modalityIntrauterine pregnancyClomiphene citrateEctopic pregnancyInfertile womenResultsAmong womenMultivariable analysisPatency assessmentTreatment armsTreatment trialsPregnancy rateMethodsSecondary analysisHysterosalpingogramLarge cohortTubes patentPatency
2017
Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype
Engmann L, Jin S, Sun F, Legro RS, Polotsky AJ, Hansen KR, Coutifaris C, Diamond MP, Eisenberg E, Zhang H, Santoro N, Network R, Bartlebaugh C, Dodson W, Estes S, Gnatuk C, Ober J, Brzyski R, Easton C, Hernandez A, Leija M, Pierce D, Robinson R, Awonuga A, Cedo L, Cline A, Collins K, Krawetz S, Puscheck E, Singh M, Yoscovits M, Barnhart K, Lecks K, Martino L, Marunich R, Snyder P, Alvero R, Comfort A, Crow M, Schlaff W, Casson P, Hohmann A, Mallette S, Christman G, Ohl D, Ringbloom M, Tang J, Bates G, Mason S, DiMaria N, Usadi R, Lucidi R, Rhea M, Baker V, Turner K, Trussell J, DelBasso D, Huang H, Li Y, Makuch R, Patrizio P, Sakai L, Scahill L, Taylor H, Thomas T, Tsang S, Yan Q, Zhang M, Haisenleder D, Lamar C, DePaolo L, Guzick D, Herring A, Redmond J, Thomas M, Turek P, Wactawski-Wende J, Rebar R, Cato P, Dukic V, Lewis V, Schlegel P, Witter F. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. American Journal Of Obstetrics And Gynecology 2017, 216: 493.e1-493.e13. PMID: 28104402, PMCID: PMC5420474, DOI: 10.1016/j.ajog.2017.01.003.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeNon-Hispanic black womenNon-Hispanic whitesOvarian syndromeMetabolic syndromeNon-Hispanic blacksHispanic womenInsulin resistanceCardiovascular diseaseHigh prevalenceEthnic differencesType 2 diabetes mellitusLower serum triglyceride levelsNon-Hispanic white womenLower sex hormonePrevalence of hypertriglyceridemiaFree androgen indexHomeostasis model assessmentPolycystic ovary syndromeBody mass indexMetabolic phenotypeSerum triglyceride levelsType 2 diabetesBlack womenAndrogen index